ARTICLE | Company News
Boehringer Ingelheim, Horizon Pharma deal
May 30, 2016 7:00 AM UTC
Boehringer Ingelheim granted Horizon exclusive rights to develop and commercialize interferon (IFN) gamma-1b outside of the U.S., Canada and Japan, where Horizon already holds rights. Boehringer will receive EUR25 million ($28 million) up front. Horizon said Boehringer markets the drug as Imukin, Imukine, Immukin and Immukine in about 30 countries, where it is approved to treat chronic granulomatous disease (CGD) and severe, malignant osteoporosis. Horizon markets the drug as Actimmune in the U.S. Horizon is also developing interferon gamma-1b to treat Friedreich’s ataxia. ...